Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance.
作者： Rita Nahta
DOI: 10.1155/2012/648965
关键词:
摘要: Resistance to the HER2-targeted antibody trastuzumab is a major clinical concern in treatment of HER2-overexpressing metastatic breast cancer. Increased expression or signaling insulin-like growth factor-I receptor (IGF-IR) has been reported subset cell lines and samples derived from trastuzumab-resistant cancers. Genetic pharmacologic inhibition IGF-IR shown improve response trastuzumab-naive models. In this paper, we will discuss role resistance. Further, cotargeting HER2 as potential therapeutic strategy for HER2-over-expressing cancers that have progressed on treatment.
hindawi.com参考文章(50)
Francisco J. Esteva, Hua Guo, Siyuan Zhang, Cesar Santa-Maria, Steven Stone, Jerry S. Lanchbury, Aysegul A. Sahin, Gabriel N. Hortobagyi, Dihua Yu, PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. American Journal of Pathology. ,vol. 177, pp. 1647- 1656 ,(2010) , 10.2353/AJPATH.2010.090885
Sylvia Shabaya, Rita Naht, Novel Therapeutic Strategies and Combinations for HER2-Overexpressing Breast Cancer InTech. ,(2011) , 10.5772/20324
Marianna Zavodovskaya, Michael J. Campbell, Betty A. Maddux, Laura Shiry, Geoffrey Allan, Leslie Hodges, Peter Kushner, John A. Kerner, Jack F. Youngren, Ira D. Goldfine, Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells. Journal of Cellular Biochemistry. ,vol. 103, pp. 624- 635 ,(2008) , 10.1002/JCB.21435
Lu-Hai Wang, Joseph L.-K. Chan, Wei Li, Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells. International Journal of Cancer. ,vol. 121, pp. 157- 164 ,(2007) , 10.1002/IJC.22606
Rinat Yerushalmi, Karen A. Gelmon, Samuel Leung, Dongxia Gao, Maggie Cheang, Michael Pollak, Gulisa Turashvili, Blakes C. Gilks, Hagen Kennecke, Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes Breast Cancer Research and Treatment. ,vol. 132, pp. 131- 142 ,(2012) , 10.1007/S10549-011-1529-8
Maurizio Scaltriti, Pieter J. Eichhorn, Javier Cortés, Ludmila Prudkin, Claudia Aura, José Jiménez, Sarat Chandarlapaty, Violeta Serra, Aleix Prat, Yasir H. Ibrahim, Marta Guzmán, Magui Gili, Olga Rodríguez, Sonia Rodríguez, José Pérez, Simon R. Green, Sabine Mai, Neal Rosen, Clifford Hudis, José Baselga, Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+breast cancer patients Proceedings of the National Academy of Sciences. ,vol. 108, pp. 3761- 3766 ,(2011) , 10.1073/PNAS.1014835108
Rita Nahta, Takeshi Takahashi, Naoto T. Ueno, Mien-Chie Hung, Francisco J. Esteva, P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells Cancer Research. ,vol. 64, pp. 3981- 3986 ,(2004) , 10.1158/0008-5472.CAN-03-3900
Rita Nahta, Francisco J. Esteva, In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells. Cancer Chemotherapy and Pharmacology. ,vol. 53, pp. 186- 190 ,(2004) , 10.1007/S00280-003-0728-3
Carlos L. Arteaga, Mark X. Sliwkowski, C. Kent Osborne, Edith A. Perez, Fabio Puglisi, Luca Gianni, Treatment of HER2-positive breast cancer: current status and future perspectives Nature Reviews Clinical Oncology. ,vol. 9, pp. 16- 32 ,(2012) , 10.1038/NRCLINONC.2011.177
Rita Nahta, Linda X.H. Yuan, Bing Zhang, Ryuji Kobayashi, Francisco J. Esteva, Insulin-like Growth Factor-I Receptor/Human Epidermal Growth Factor Receptor 2 Heterodimerization Contributes to Trastuzumab Resistance of Breast Cancer Cells Cancer Research. ,vol. 65, pp. 11118- 11128 ,(2005) , 10.1158/0008-5472.CAN-04-3841